Related Experiment Video
Updated: Jan 5, 2026
Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
Published on: December 7, 2019
Toward personalized TGFβ inhibition for pancreatic cancer
Ryan M Carr1, Martin E Fernandez-Zapico1
1Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Abstract:
Cancer can be conceptualized as arising from somatic mutations resulting in a single renegade cell escaping from the constraints of multicellularity. Thus, the era of precision medicine has led to intense focus on the cancer cell to target these mutations that result in oncogenic signaling and sustain malignancy. However, in pancreatic ductal adenocarcinoma (PDAC) there are only four abundantly common driver mutations (KRAS, CDKN2A, TP53, and SMAD4), which are not currently actionable. Thus, precision therapy for PDAC must look beyond the cancer cell. In fact, PDAC is more than a collection of renegade cells, instead representing an extensive, supportive ecosystem, having developed over several years, and consisting of numerous interactions between the cancer cells, normal mesenchymal cells, immune cells, and the dense extracellular matrix. In this issue, Huang and colleagues demonstrate how elucidation of these complex relationships within the tumor microenvironment (TME) can be exploited for therapeutic intervention in PDAC. They identify in a subset of PDAC with mutations in TGFβ signaling, that a paracrine signaling axis can be abrogated to modulate the TME and improve outcomes.
Insights
Precision medicine for pancreatic cancer must target the tumor microenvironment (TME). Researchers found that blocking a specific signaling pathway in pancreatic ductal adenocarcinoma (PDAC) can alter the TME and improve patient outcomes.
Area of Science:
- Oncology
- Cancer Biology
- Tumor Microenvironment Research
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is characterized by a few common, non-actionable driver mutations (KRAS, CDKN2A, TP53, SMAD4).
- The tumor microenvironment (TME), comprising cancer cells, stromal cells, immune cells, and extracellular matrix, plays a critical role in PDAC progression.
- Current precision medicine approaches focusing solely on cancer cell mutations are insufficient for effective PDAC therapy.
Purpose of the Study:
- To investigate therapeutic strategies targeting the complex ecosystem of PDAC beyond cancer cell-intrinsic mutations.
- To explore the potential of modulating the tumor microenvironment (TME) for improved treatment outcomes in PDAC.
- To identify actionable targets within the PDAC TME, particularly in tumors with specific signaling pathway mutations.
Main Methods:
- Analysis of the interactions between cancer cells, stromal cells, immune cells, and the extracellular matrix in PDAC.
- Investigation of specific genetic alterations, such as mutations in TGFβ signaling pathways, within PDAC.
- Elucidation of paracrine signaling axes within the PDAC tumor microenvironment.
Main Results:
- The study identified a subset of PDAC with mutations in TGFβ signaling.
- A paracrine signaling axis within the TME was identified and shown to be abrogate-able.
- Modulation of this paracrine signaling axis led to alterations in the TME and improved outcomes in PDAC.
Conclusions:
- Therapeutic interventions targeting the tumor microenvironment (TME) are crucial for treating pancreatic ductal adenocarcinoma (PDAC).
- Abrogating specific paracrine signaling axes, such as those involving TGFβ, can effectively modulate the PDAC TME.
- Exploiting the complex ecosystem of PDAC offers promising avenues for developing novel precision therapies.
More Related Videos
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Related Concept Videos
01:16TGF - β Signaling Pathway
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...